Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics (NASDAQ: ALLO) presented interim results from its Phase 1 TRAVERSE trial for ALLO-316, a CAR T candidate targeting CD70 in renal cell carcinoma (RCC), at the AACR Annual Meeting on April 17, 2023. The trial enrolled 19 patients, with 10 exhibiting CD70 expression. Notably, three of those patients achieved a partial response, contributing to a 100% disease control rate among CD70+ patients. ALLO-316 utilizes proprietary Dagger™ technology to enhance cell expansion and persistence while resisting rejection. As of March 23, 2023, the trial has shown early signs of tumor activity, with further dose escalation ongoing. The overall disease control rate across all patients reached 89%. Initial safety results indicated a manageable adverse event profile, with no instances of ICANS or graft-versus-host disease reported.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced its participation in four upcoming investor conferences. These events include:

• Canaccord Genuity - CG Horizons in Oncology Virtual on April 20, 2023, at 8:00 AM PT
• BofA Securities 2023 Health Care Conference on May 10, 2023, at 4:20 PM PT
• The JMP Securities Life Sciences Conference on May 15, 2023, at 8:30 AM PT
• 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023, at 1:35 PM PT

Webcasts of these events will be available on the company’s website under the Investors tab. Allogene Therapeutics focuses on developing allogeneic CAR T products aimed at improving cancer treatment, striving to provide 'off-the-shelf' therapies for patients.

Allogene Therapeutics (Nasdaq: ALLO) announced interim data from its Phase 1 TRAVERSE trial for ALLO-316, targeting renal cell carcinoma (RCC) patients who previously received immune therapies. The results will be presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2023. Initial data show ALLO-316 exhibits antitumor activity and utilizes Dagger™ technology to mitigate immune rejection. The U.S. FDA granted Fast Track Designation to ALLO-316 in March 2022, highlighting its potential for treating difficult RCC cases. The ongoing trial will assess safety, tolerability, and effectiveness while exploring patient selection through a new diagnostic assay.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotech firm, announced its participation in two significant investor conferences. The Cowen 43rd Annual Health Care Conference will occur on March 6, 2023, at 8:10 AM PT, while the Oppenheimer 33rd Annual Healthcare Conference is set for March 14, 2023, at 9:00 AM PT. Webcasts will be available on their website, along with replays accessible for 30 days. Allogene is known for developing off-the-shelf CAR T cell therapies for cancer. For more details, visit www.allogene.com.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced the publication of a case study in Molecular Therapy focusing on a single patient who experienced a chromosomal rearrangement after receiving the gene-edited CAR T treatment, ALLO-501A. The investigation determined that the chromosomal inversion was unrelated to gene editing or manufacturing processes, and held no clinical significance. Following a clinical hold by the FDA due to initial concerns, the hold was lifted three months later. This case reinforces the understanding of genomic variability in CAR T treatments and highlights the importance of cell-intrinsic biology in therapeutic applications.

Allogene Therapeutics (Nasdaq: ALLO) announced the initiation of the industry's first potentially pivotal Phase 2 allogeneic CAR T trial, ALPHA2, for relapsed/refractory large B cell lymphoma, enrolling 100 patients. Data shows comparable six-month progression-free survival to autologous therapies. The company reported a net loss of $94.8 million for Q4 2022, totaling $332.6 million for the year. Allogene ended 2022 with $576 million in cash and expects a $250 million decrease in cash reserves for 2023, with a runway into 2025. Financial guidance includes $350 million in GAAP operating expenses.

Allogene Therapeutics (Nasdaq: ALLO) will report its fourth quarter and year-end 2022 financial results on February 28, 2023, following a conference call at 2:00 PM PT/5:00 PM ET. Investors can listen to the live audio webcast on the company's website, which will be available for replay for 30 days. Allogene is focused on developing allogeneic CAR T products for cancer and aims to create readily available cell therapies. The company highlights ongoing efforts in the cell therapy space and emphasizes its management team's expertise.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) recently presented preclinical data on its innovative Dagger technology at the Keystone Symposia in Banff, Canada. This new platform aims to prevent immune rejection of AlloCAR T cells, allowing for enhanced persistence and efficacy against cancer. The Dagger technology is integral to ALLO-316, targeting CD70 in renal cell carcinoma within the ongoing Phase 1 TRAVERSE study. Preclinical findings indicate improved AlloCAR T cell survival and effectiveness in targeting tumors. The firm plans to leverage this technology across various hematologic malignancies and solid tumors, aiming to advance patient outcomes.